This trial is evaluating whether Palbociclib will improve 1 primary outcome and 5 secondary outcomes in patients with Brain Cancer. Measurement will happen over the course of 8 Weeks.
This trial requires 30 total participants across 2 different treatment groups
This trial involves 2 different treatments. Palbociclib is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Approximately 9.3 million new cases of brain cancer will occur in the United States in 2004. Of this, 4.1 million will occur in men and 4.1 million will occur in women. The number of people who develop brain cancer during their lifetime is estimated at 420,000.
Only a short list of treatment options are commonly used for brain cancers, but treatment depends heavily on the type of tumor, how fast it has grown, and how quickly it is detected.\n
Most of the symptoms may be caused by a stroke, migraine, and intracranial tumour. Thus, brain imaging and thorough neurological and neuropsychiatric investigations may be helpful in differential diagnosis. However, most of the symptoms are nonspecific and may be associated with other diseases like brain abscess, intracranial haematoma or other intracranial tumours.
A large number of cancer survivors (approximately 30%) may have a brain tumour, yet nearly half (43%) of these patients will not be referred to an oncologist. If left untreated, brain cancer is a serious cause of pain and disability. Brain cancer patients often present with severe, distressing symptoms which frequently occur in patients with other serious conditions and that are difficult to manage adequately. Thus, patients presenting with brain cancer can benefit from multidisciplinary teams.
Brain cancer is almost always lethal and can be cured only with surgery. However, in selected individuals surgery has high cure rates in the longer term.
No new therapeutic approaches for treating tumors of the brain have been found up until today, so it is yet unknown what new possibilities exist for treatments of [brain cancer](https://www.withpower.com/clinical-trials/brain-cancer). Brain tumors are often metastatic, so the treatment of the primary tumor is not possible. Most patients suffering from brain cancer are in the terminal stage of the disease. However, some new treatments may become available sooner and thereby prolong life. At least one promising therapy has been tested in patients with glioblastoma, as this type of cancer is the most advanced. It was found that patients suffering from brain cancer can live a month longer while on treatment. This treatment, called temozolomide, has been found more effective than treatment with corticosteroids.
While the symptoms may vary depending on the cancer type, some brain tumors can cause a patient to become inactive, anxious, irritable or even comatose. This will impact on many people adversely. Also, brain tumors can have a negative effect on an individual’s mental faculties, as well as the cognitive abilities of the patient. Even though tumors may have a negative impact on a patient's ability to cope, it is important to understand that it can be possible to overcome an advanced stage brain tumor. With the correct treatments and a positive attitude towards life, an individual can overcome severe negative consequences. It remains the individual’s life and future. It is vital for a proper treatment and medical diagnosis to be taken.
For men and women who had been diagnosed with [brain cancer](https://www.withpower.com/clinical-trials/brain-cancer), the mean age of first diagnosis was 74.3 and 71.5 years, respectively. Among both men and women, however, a greater proportion of younger patients were diagnosed with brain cancer versus cancer elsewhere in the head and neck. The proportion of younger patients with brain cancer increased steadily from 1983 through 2001. In 1991, more than 30% of the patients diagnosed with brain cancer were less than 50 years old. More than half of the patients who had brain cancer were diagnosed between 70 and 79 years of age. Most patients with brain cancer who were diagnosed between the 50s and 60s were not under 60 years old.
There is no good evidence for the superiority of any therapy for relieving symptoms. However, some drugs may produce slight improvements in function. Treatment for [brain cancer](https://www.withpower.com/clinical-trials/brain-cancer) is extremely difficult to standardise, and there is no good evidence of which treatment is best for everybody. There are several well-studied drugs and treatments for advanced cancer. A survey of current research indicates there are no high-quality studies on which treatment is preferable for every type of brain tumour. There is good evidence that chemotherapy is useful in relieving some symptoms. Surgery may help to improve symptoms for patients with a small tumour, but for most adults, surgery alone was not an effective symptom-relief treatment.
This research presents the possibility that our current understanding of brain cancer may be flawed and lead us to overemphasize the role of genetics, as well as the role of exposure. These facts highlight the need for new methods of researching, and possibly treating, brain cancer..
It is estimated that 50 to 70% of breast cancer patients have alterations of the ER-1/estrogen receptor pathway as well as a subset of high-grade, ER-/PT-negative metastatic breast cancer patients. These patients are not typically candidates to receive standard endocrine therapy but are often treated with palbociclib. Data from a recent study demonstrates that in nearly all patients treated with palbociclib, the drug is very effective at controlling estrogen receptor-positive, ER- tumors but does not seem to have an obvious effect in ER-/PT- tumors.